Application Effect of Qingyuan Shenghua Decoction Combined with Ulinastatin in Severe Pneumonia Patients
Objective To explore the application effect of Qingyuan Shenghua decoction combined with Ulinastatin in severe pneumonia patients.Methods In this study,patients with severe pneumonia in the Third People's Hospital of Henan Province were selected as the research objects,and 90 patients who met the inclusion and exclusion criteria were selected from October 2019 to October 2022.Patients were separated into observation and control groups using the coin toss approach,with 46 cases in each group.Both groups received basic intervention;the control group received ulinastatin,while the observation group received both ulinastatin and Qingyuan Shenghua decoction.Both groups were treated for seven days.The two groups were compared in terms of total effective rate,inflammatory indicators,immune function-related indicators,lung function indicators,prognosis ratings,and adverse reaction incidence.Results The total effective rate of observation group(91.30％)was higher than that of control group(76.09％),and the difference was statistically significant(X2=3.903,P=0.048).Before intervention,there was no significant difference in the level of inflammatory indicators between the two groups(P＞0.05).After 7 days of intervention,the levels of inflammatory indicators in both groups were decreased(P＜0.001),and the observation group was lower than the control group(P＜0.05).Before intervention,there was no statistically significant difference in immune function between the two groups(P＞0.05).After intervention,the levels of CD3+,CD4+,CD4+/CD8+in the two groups increased(P＜0.05),CD8+was not significantly increased(P＞0.05).The observation group had significantly greater levels of CD3+,CD4+,and CD4+/CD8+compared to the control group(P＜0.05).Before the intervention,there was no significant difference in forced expiratory volume in one second as a percentage of predicted value(FEV1％)or forced expiratory volume in one second/forced vital capacity(FEV1/FVC)between the two groups(P＞0.05).After intervention for 7 days,the pulmonary function indexes of the two groups were increased(P＜0.05),and observation group was higher than control group(P＜0.05).Before intervention,there was no significant difference in prognostic scores between the two groups(P＞0.05).After 7 days of intervention,scores in both groups decreased(P＜0.05).The observation group was significantly lower than the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group(10.87％)and the control group(13.04％)(x2=0.103,P=0.748).Conclusion The combination of Qingyuan Shenghua decoction and ulinastatin can improve the immune and lung function of pneumonia patients,exert lung protective effects,reduce inflammatory reactions,improve treatment effectiveness,improve prognosis,and is relatively safe.
NETL
NSTL
万方数据
